ZINGO

This brand name is authorized in Hong Kong, United States

Active ingredients

The drug ZINGO contains one active pharmaceutical ingredient (API):

1 Lidocaine UNII V13007Z41A - LIDOCAINE HYDROCHLORIDE

Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane. Read about Lidocaine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ZINGO Powder intradermal injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N01BB02	Lidocaine	N Nervous system → N01 Anesthetics → N01B Anesthetics, local → N01BB Amides
Discover more medicines within N01BB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: HK	Department of Health Drug Office	Identifier(s): 65250
Country: US	FDA, National Drug Code	Identifier(s): 70645-123